

Grant agreement no. 282586
 ROAMER: A road-map for mental health research in Europe
 Coordination and Support Action
 Objective THEME [HEALTH.2011.3.3-4]

CENTRAL DATABASE

DELIVERABLE REFERENCE NUMBER AND TITLE: D2.2

DUE DATE OF DELIVERABLE: month 15

ACTUAL SUBMISSION DATE: 31/05/13

START DATE OF PROJECT: October the 1st 2011

DURATION: 36 months

ORGANISATION NAME OF LEAD BENEFICIARY FOR THIS DELIVERABLE:

AUTHORS

CIBERSAM-PSSJD (COORD)	Dr. Josep Maria Haro, Dr. Carla Obradors
MUMC (WP2)	Prof. Jim van Os, Dr. Rebecca Kuepper
FONDAMENTAL (WP3)	Prof. Marion Leboyer, Dr. Matthias Brunn, Dr Karine Chevreul (URC ECO), Pr Jacques Demotes (INSERM), Jean-Baptiste Hazo
SE (WP10)	Prof. Istvan Bitter, Dr. Szilvia Papp

APPROVAL

WORK-PACKAGE LEADERS	MUMC (WP2)	Prof. Jim van Os
PROJECT COORDINATOR	CIBERSAM-PSSJD	Dr. Josep Maria Haro

AUTHORISATION

PROJECT OFFICER	EUROPEAN COMMISSION	Mrs. Caroline Attard
------------------------	----------------------------	----------------------

HISTORY RECORD

ISSUE	DATE	WRITER	NOTES
D2.2 first draft	January-March 2013	Dr Carla Obradors Dr. Matthias Brunn Jean-Baptiste Hazo Dr. Szilvia Papp	
D2.2 review	March-May 2013	Dr. Josep Maria Haro Prof. Jim van Os Dr. Rebecca Kuepper	

- Interim report -

D2.2 submission

31/05/13

Prof. Marion Leboyer
Dr Karine Chevreul (URC ECO)
Pr Jacques Demotes (INSERM)
Prof. Istvan Bitter
All

Project co-funded by the European Commission within the Seventh Framework Programme (2007-2013)		
Dissemination Level		
PU	Public	X
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	

Table of contents

1. Introduction.....	4
2. Objectives	4
3. Methods.....	4
3.1. Database for European funding, infrastructures, and training programs to support MH&WB research .	5
3.1.1. European funding to support MH&WB research	5
3.1.2. European infrastructures to support MH&WB research	5
3.1.3. European training programs to support MH&WB research	5
3.2. Database for MH&WB research groups in Europe	6
4. Results	8
5. Procedures for protection of privacy.....	8
6. Publications resulting from the work described.....	9
7. Abbreviations	9
8. Bibliography	9
Annexes.....	10
Annex I. European funding to support MH&WB research.....	10
Annex II. Results display of the database on European training programs to support MH&WB research.....	18
Annex III. Database for MH&WB research groups in Europe	20

1. Introduction

The ROAMER project seeks to meet the essential need for a coordinated and comprehensive approach to the promotion and integration of research in mental health (MH) and well-being (WB) by means of an effective and widely accepted **Roadmap**. The roadmap is aimed to priority setting across Europe and the rest of the world, focusing on high quality scientific research and taking into account the priorities set out in the European Parliament Resolution, namely "prevention, early detection, intervention and treatment of mental disorders", and will establish infrastructure and capacity requirements of mental health and wellbeing research in Europe in the short, middle and long-term and as applicable across the life time.

In this context, it has been necessary to develop an accurate picture of the state-of-art of mental health research in Europe, both in general terms and with respect specifically to each track of mental disorder (MD), mental health and wellbeing research (biomedical, psychological, social and economical aspects, public health and well-being), in order to find gaps and to define salient advances.

Accordingly to the grant agreement, all results achieved by ROAMER will be made publicly available for the benefit of research in the domain. Therefore, after the review of the state of art, the ROAMER consortium has set a central database that integrates information about the current scenario from the different tracks (WP3 to 8) including different disciplines and countries, from a life-span perspective.

Up to now, the database is divided into two sections that will be explained in deep in next chapters:

1. Database for European funding, infrastructures, and training programs to support MH&WB research
2. Database for MH&WB research groups in Europe

2. Objectives

The main goal of the D2.2 [Central Database] is to integrate and make searchable and available for further exploitation information about the current scenario of the different tracks (WP3 to 8) of European MH & WB Research including different disciplines and countries, and from a life-span perspective.

3. Methods

According to the Description of Work, P5 MUMC, in close collaboration with all partners but specially with CO1 CIBERSAM, P3 Fundamental and P11 SE, has developed a central database that includes two sections:

1. Database for European funding, infrastructures, and training programs to support MH&WB research
2. Database for MH&WB research groups

The database is presented in Excel format (though in annexes, some extractions are shown as examples) and is also being implemented online within the website of ROAMER (www.roamer-mh.org) under section <Resources>.

The online database includes a user-friendly search tool that allows the visitor to seek the information needed.

3.1. Database for European funding, infrastructures, and training programs to support MH&WB research

This database comprises information of national funding agencies (see section 3.1.1 for more details), infrastructures (see section 3.1.2 for more details) and training programs (see section 3.1.3 for more details) that support MH&WB research in Europe.

3.1.1. European funding to support MH&WB research

This database comprises the most relevant national funding agencies that support MH&WB research in European countries, including some Science Europe member organizations (<http://www.scienceurope.org/about-us/member-organisations>).

The information has been collected thanks to web searches, data from other databases such as that of the National Science Foundation (<http://www.nsf.gov/index.jsp>), data of the literature (Chevreul and al., 2012), results of the survey consultations, the collaboration of members of the ROAMER consortium and experts participating in any WP, and the direct contact with the funding agencies.

This database provides information regarding the following fields:

- Name of the funding agency
- Country (i.e., any EU-27 country)
- Public/private
- Contact details
- Website

The data will be periodically revised and updated during the progression of the ROAMER project. The database is still incomplete and under revision. Most of the data will be updated from the ROAMER's general survey results that will be launched in June 2013. The tentative information is shown in Annex I, and will be uploaded online in the web of ROAMER under section <Resources> soon.

3.1.2. European infrastructures to support MH&WB research

This database contains the most relevant European and national infrastructures that support MH&WB research in any European country.

The WP3 has contacted the data collection in partnership with with the MERIL [Mapping of the European Research Infrastructure Landscape] project, that has very recently gone online with a beta version (<http://portal.meril.eu>). WP3 has asked for an extraction, authorisation and screen for relevant infrastructures. The relevant data for mental health research is being collected and will be uploaded in the web of ROAMER under the section <Resources > very soon. MERIL project will be acknowledged and linked in our website.

The data will be periodically revised and updated during the progression of the ROAMER project.

3.1.3. European training programs to support MH&WB research

This database comprises the most relevant courses and training programs that support MH&WB research in any European country.

- Interim report -

For the collection of data, WP3 has contacted the coordinators of ON-COURSE database and asked for extraction, authorisation and screen for relevant information regarding the mental health courses. It is been agreed that ROAMER can make public the data on its website with a reference to their site (<http://www.on-course.eu/>).

The database provides information regarding the following fields:

- Name of the program
- Description of the program
- Type of teaching (with multiple choices)
- Countries
- City
- Starting month
- Full time duration
- Part time duration
- Total program fees for European citizens (in Euros)
- Learning context (multiple choices)
- Type of credits
- Language
- Scientific areas
- Therapeutic areas
- Methodologies
- Auxiliary skills
- Course contact
- Administrative contact
- Course provider

The database is provided in Excel format (document attached). It has being also implemented online within the website of ROAMER (www.roamer-mh.org) under section <Resources>. The online database includes a user-friendly search tool that allows the visitor to seek the information needed (see some examples of the results display in Annex II).

Although the electronic tool is still being tested, it can be provisionally visited through the following link:
<http://roamer.usn.hu/search.php>.

The data will be periodically revised and updated during the progression of the ROAMER project.

3.2. Database for MH&WB research groups in Europe

This database comprises the most relevant researchers in MH&WB of each European country. Therefore, it includes:

- Principal investigators of the ROAMER consortium
- Experts participating in any WP of ROAMER who accomplish all criteria described in section 5.3.2 of the [D2.1 - Guidelines to harmonise the project] and that are summarized below:
 - The candidate should count with a wide expertise in the area of knowledge of the WP (e.g. demonstrated by the number of publications on the specific research field and their impact in the scientific community)
 - The H-value > 10, as an indicator of the relevance/excellence of the scientific career of the expert (unless in WPs where the leader consider that the number of publications in peer-reviewed journals and of citations is not a good indicator of the excellence of the candidate in the field)

- Interim report -

- At least one expert of the WP should be from the East Europe, as an indicator of the geographic representation
 - At least 20% of experts within the WP should be women or men, as an indicator of the gender representation
 - The list of experts should include also young scientists that can contribute with an innovative point of view
- European researchers that participated the NIMH grand challenges survey (Collins et al., 2011).
 - Researchers that have published the most articles in the field during the last 5 years in each EU-country. To identify these names, the Web of Knowledge was used. The search was done using the same common search terms defined for the systematic mapping of the literature (see annexes II and III of the D2.1), limited for the corresponding period of time (from 2008 to date) and for each specific EU-27 country. The top authors within the hits obtained for each country were collected. The number of authors selected for each country depend on the number of hits obtained as detailed below:

Number of hits of the country	Number of invited authors from that country
< 100	5
100 - 1000	10
1.000 - 2.500	25
2.500 - 5.000	50
5.000 - 20.000	100
> 20.000	200

- The list has been complemented with experts suggested by WP leaders and partners in order to balance it in terms of area of expertise if necessary

The database provides information regarding the following fields:

1. Name of the principal investigator (Author)

2. Country

e.g.:	Austria	Belgium	Bulgaria
	Cyprus	Czech Republic	Denmark
	Estonia	Finland	France
	Germany	Greece	Hungary
	Ireland	Italy	Latvia
	Lithuania	Luxembourg	Malta
	Netherlands	Poland	Portugal
	Romania	Slovakia	Slovenia
	Spain	Sweden	United Kingdom
	Croatia	Former Yugoslav Republic of Macedonia	Iceland
	Montenegro	Turkey	Albania
	Andorra	Armenia	Azerbaijan
	Belarus	Bosnia and Herzegovina	Georgia
	Liechtenstein	Moldova	Monaco
	Norway	Russia	San Marino
	Serbia	Switzerland	Ukraine

3. Research area

e.g.:	Clinical research (non-interventional)	Clinical trials (interventional)
	Basic research	Epidemiology/public health research
	Health services research	Other

4. Concerns (mental disorders they study)

e.g.:	Schizophrenia and Non-affective Psychosis	Bipolar Disorders
	Depressive Disorders	Anxiety Disorders

Dementia	ADHD
Trauma- and Stress-Related Disorders	Dissociative Disorders
Somatoform and Somatic Symptom Disorders	Personality Disorders
Substance Use and Addictive Disorders	Mental Retardation
Autism and Other Neurodevelopment disorders	Eating Disorders
Disruptive, Impulse Control, and Conduct Disorders	High risk groups
General population	Other

5. Size of the research group (number of investigators)

6. Participation in ROAMER

e.g.:	Coordinator	WP2 - leader	WP3 - leader	WP4 - leader
	WP5 - leader	WP6 - leader	WP7 - leader	WP7 - co-leader
	WP8 - leader	WP2 - Expert	WP3 - Expert	WP4 - Expert
	WP5 - Expert	WP6 - Expert	WP7 - Expert	WP8 - Expert
	Scientific Advisory Board	Stakeholder Advisor Board	Surveys	Other

The email address of researchers will not be made public to keep their privacy (see chapter 5 for more details).

The data will be periodically revised and updated during the progression of the ROAMER project. The database is still incomplete because most of the data will be collected from the general survey of ROAMER that will be launched in June 2013. The electronic tool is being tested and will be uploaded in the web of ROAMER under the section <Resources>. The tentative information is shown in Annex III.

4. Results

The data will be periodically revised and updated during the progression of the ROAMER project. New information is being continuously collected and integrated from all activities conducted in ROAMER. In concrete, we expect to receive many inputs from the survey consultation that will be launched in June 2013. Therefore, databases are not complete or finalised at this stage and can suffer minor changes in format and display until the end of the project, due to refinement activities.

The tentative results are shown in annexes I-III and in the document attached in Excel format. Moreover, you can visit the databases online in the webpage of ROAMER under the section <Resources> or in the following link (while the electronic tool is being tested): <http://roamer.usn.hu/search.php>.

5. Procedures for protection of privacy

Although ROAMER will only exploit high-level aggregated data, ROAMER will in any case respect the right to privacy and will deploy procedures for protecting confidential information. The obtained data will be processed fairly and lawfully for specified purposes and on the basis of the consent or other legitimate basis laid down by law. Everyone will be able to access the data which have been collected concerning him or her when asked, and will be able have it rectified if needed.

All information will be held strictly confidential. Data released through the Internet or through publications will contain no information which could lead to the identification of any individual. All data is held in highly secured environments. Transport of data will be encrypted. Access to the database will be possible at specific authorisation levels.

6. Publications resulting from the work described

The databases will be published online in the web of ROAMER under the section <Resources>.

7. Abbreviations

MH = mental health
WB = well-being
MD = Mental disorder

8. Bibliography

Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS; Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ. Grand challenges in global mental health. *Nature*. 2011 Jul 6;475(7354):27-30.

Chevreur K, McDaid D, Farmer CM, Prigent A, Park A-L, Leboyer M, et al. Public and nonprofit funding for research on mental disorders in france, the united kingdom, and the united states. *J Clin Psychiatry*. 2012 Aug;73(7):e906–912.

Annexes

Annex I. European funding to support MH&WB research

***Please note this information is provisional, incomplete and still under revision. It has been extracted from the original Excel file and it is shown just as an example.*

Country	National Funding body
Austria	<p>FWF - Fonds zur Förderung der Wissenschaftlichen Forschung/Austrian Science Fund http://www.fwf.ac.at/en/projects/index.html President dpt. Biology and Medical Sciences - Christine Mannhalter</p> <p>Austrian Research Promotion Agency (FFG) - office@ffg.at Thematic Programmes - DI Dr. Emmanuel Glenck -</p>
Belgium	<p>F.R.S. - FNRS - Fonds de la Recherche Scientifique/Fund for Scientific Research http://www.frs-fnrs.be/ MANDATS ET PROJETS - Responsable : Marie-Christine Fraselle</p> <p>FWO - Fonds voor Wetenschappelijk Onderzoek - Vlaanderen/Research Foundation Flanders http://www.fwo.be/ Medical sciences: E : med@fwo.be</p>
Bulgaria	<p>The Bulgarian Academy of Sciences Acad. Stefan VODENICHAROV, D.Sc - President Prof. Stefan Hadjitodorov - Advisor to the President of the Bulgarian Academy of Sciences</p>
Croatia	<p>Croatian Science Foundation (HRZZ) Scientific Committee for Biomedicine and Health - coordinator - Professor Boris Brkljačić, PhD, University of Zagreb, School of Medicine Maja Vaupotić, Programme Coordinator - Biomedicine and Health -</p>
Cyprus	<p>Research Promotion Foundation (RPF) National Research Programmes Unit - programme on Health and biological sciences - Dr Rebecca Chrysafi, Scientific Officer -</p>

<p>Czech Republic</p>	<p>GAČR - Grantová agentura České republiky/Czech Science Foundation info@gacr.cz http://www.gacr.cz Mrs. Blanka Javorova</p> <p>Akademie věd České republiky (ASCR) - Academy of Sciences of the Czech Republic</p> <p>The Institute of Psychology of the Academy http://www.avcr.cz/o_avcr/struktura/pracoviste/humanitni/PSU.html -- DIRECTOR <u>Prof. PhDr. Marek Blatný, CSc.</u> VICE-DIRECTOR - <u>PhDr. Martina Hřebíčková, Dr.</u></p> <p>Czech Medical Academy http://www.medical-academy.cz/cla/kontakty.html cla@medical-academy.cz</p>
<p>Denmark</p>	<p>DSF - Det Strategiske Forskningsråd/The Danish Council for Strategic Research The Programme Commission on Individuals, Disease and Society, please contact: New address: Strategic Research in Individuals, Disease and Society Special Advisor Kirsten E. Caning Head of Section Irene Bang Møller</p> <p>DFF - Det Frie Forskningsråd/Danish Council for Independent Research Danish Agency for Science, Technology and Innovation Strategic Research in Health, Food and Welfare Strategic Research in Individuals, Disease and Society</p> <p>The Danish Council for Independent Research, Medical Sciences</p> <p>Danish National Research Foundation (DNRF) Liselotte Højgaard (Chairman)</p>
<p>Estonia</p>	<p>ETAG - Eesti Teadusagentuur/Estonian Research Council Head of Estonian Research Council - Andres Koppel Deputy Head of Estonian Research Council - Toomas Meressoo Head of Dpt. Research funding - Madis Saluveer</p>
<p>Finland</p>	<p>AKA - Suomen Akatemia/Finlands Akademi/Academy of Finland Professor, Tuula Tamminen (Ms) - Research Council for Health - University of Tampere</p>

- Interim report -

<p>Former Yugoslav Republic of Macedonia</p>	<p>Ministry of Education and Science Mr Milan Drakalski. Back. Position. Head of Department of Science and Technological Development Mrs Marina Nikolovska - Health and JRC NCP</p>
<p>France</p>	<p>ANR - Agence Nationale de la Recherche/French National Research Agency Pascale Briand - Director General Jean-Michel Heard - Head of Health and Biology Department</p> <p>INSERM - Institut National de la Santé et de la Recherche Médicale/French National Institute of Health and Medical Alexis Brice - Research</p> <p>CNRS - Centre Nationale de la Recherche Scientifique/National Centre for Scientific Research Bernard POULAIN (head neuroscience centre Strasbourg)</p> <p>Fondation Fondamental Pr. Marion Leboyer – Director</p> <p>CEA (French atomic Energy Commission) Stanislas Dehaene – Director of the research unit of CEA-Inserm of cognitive imagery in Eurospin</p> <p>Institut Pasteur Thomas BOURGERON – Director of the neuro sciences department.</p>
<p>Germany</p>	<p>Programme Management Agency (PT-DLR) – Health Research, on behalf of the Federal Ministry of Education and Research (BMBF) Dr. Petra Lüers</p> <p>DFG - Deutsche Forschungsgemeinschaft/German Research Foundation www.dfg.de Mädge, Britta Dr. Psychiatry, Psychotherapy, Psychosomatic Medicine</p> <p>Federal Ministry of Education and Research (BMBF) Dr. Georg Schütte Directorates General "Key Technologies - Research for Innovation," "Life Sciences - Research for Health</p>
<p>Greece</p>	<p>Foundation for Research and Technology-Hellas (FORTH) central@admin.forth.gr</p> <p>National Strategic Reference Framework (NSRF): Managing Authority of the OP Health and Social Solidarity</p>

- Interim report -

<p>Hungary</p>	<p>OTKA - Országos Tudományos Kutatási Alapprogramok/Hungarian Scientific Research Fund Studium Irodaház. Levélcím László Péter Kollár - President of OKTA Board Anna Erdei - President of the Council of Life Sciences</p>
<p>Iceland</p>	<p>Rannís -Rannsóknamiðstöð Íslands/Iceland Centre for Research http://www.rannis.is/english Icelandic Research Fund - Board of the IRF is appointed by the Minister of Education, Science and Culture Guðlaug Þóra Kristjánsdóttir - Officer Health science and life sciences</p>
<p>Ireland</p>	<p>HRB - Health Research Board Dr Declan Bedford (Chairman) Research Strategy and Funding Directorate Jim Breslin (Chairman): Department of Health and Children Brendan Ingoldsby: Department of Health and Children Dr Tony Holohan: Department of Health and Children</p>
<p>Italy</p>	<p>CNR - Consiglio Nazionale delle Ricerche/National Research Council Prof. Luigi Nicolais (President) The Italian Ministry of Education, University and Research: Dpt. per l'università, l'AFAM e per la ricerca - Head: Raffaele Liberali Direzione generale per il coordinamento e lo sviluppo della ricerca- Direttore Generale: Dott. Emanuele Fidora - Progetti di Ricerca di Interesse Nazionale - PRIN - - Fund for investment in basic research (Fondo per gli Investimenti della Ricerca di Base - FIRB)</p>
<p>Latvia</p>	<p>LZP - Latvijas Zinatnes Padome/Latvian Science Council Ministry of Health- Māris Taube Latvian Academy of Sciences - Bruno Andersons</p>
<p>Lithuania</p>	<p>LMT - Lietuvos Mokslo Taryba/Research Council of Lithuania Dainius Puras (in representation of the Research Council) Professor and Chair, Centre of Child Psychiatry and Social Paediatrics Clinic of Psychiatry Vilnius university</p>

<p>Luxembourg</p>	<p>FNR - Fonds National de la Recherche/National Research Fund Dr Marc Schiltz (Secretary General, Executive Head of the FNR) Dr Olga de Brito (Programme Manager - AFR Contact for Biology, Medical Sciences) Marie-Claude Marx, PhD (Programme Manager - AFR Contact for Biology, Medical Sciences..) Frank Glod, PhD (Contact for Biomedical Sciences)</p>
<p>Malta</p>	<p>Malta Council for Science and Technology (MCST) Vice Chairman & Chief Executive Officer Dr Ing. Nicholas Sammut Ph.D. Director, R&I National Funding and Technology Commercialisation Ing. Joseph Sammut Executive Science & Technology Officer- Dr Elena Yasnetskaya</p>
<p>Montenegro</p>	<p>Ministry of Science</p>
<p>Netherlands (Holland)</p>	<p>Dutch Health Research Council (ZONMw) Edvard Beem co-director Netherlands Organisation for Health Research and Development (ZonMw): Health Promotion and Disease Prevention Programme - Jeanet Bruil- Health care efficiency research - Vivienne Lahaut Translational Research - Janine Blom NWO - Nederlandse Organisatie voor Wetenschappelijk Onderzoek/Netherlands Organisation for Scientific Research Marianne de Visser (member of the Governing Board - medicine, neurologist)</p>
<p>Norway</p>	<p>RCN - Norges Forskningsråd/Research Council of Norway Jesper W. Simonsen (Director Division for Society and Health)- Mari Kristine Nes (Director department for Health) - Hilde Jerkø (Director Department for Medicine, Natural Sciences and Technology) Ole Andreassen - Chair of Programme for Mental Health, The Norwegian Research Council</p>



- Interim report -

Poland	<p>NCN - Narodowe Centrum Nauki/National Science Centre --> ONLY BASIC RESEARCH Deputy director - Justyna Woźniakowska Council chairman - prof. dr hab. Michał Karoński</p> <p>NCBR - The national center for research and development - funding agency supporting applied research and knowledge transfer) http://www.ncbir.pl/en/</p> <p>Poland Ministry of Science & Higher Education (NAUKA) - Department of Scientific Policy Instruments - Magdalena Maciejewska</p>
Portugal	<p>FCT - Fundação para a Ciência e a Tecnologia/Foundation for Science and Technology -</p> <p>Life and Health Sciences Scientific Council: President: Catarina Resende Oliveira</p>
Romania	<p>National Research Council (CNCS) Dr. IONAC Mihai Edmond - Medical sciences</p>
Serbia	<p>Ministry of Education, Science and Technological Development Cabinet of the Minister of Education and Science</p>
Slovakia	<p>APVV - Agentúra na podporu výskumu a vývoja/Slovak Research and Development Agency The council of medicine sciences President - prof. MUDr. Ján Danko, CSc.</p>
Slovenia	<p>ARRS - Javna agencija za raziskovalno dejavnost Republike Slovenije/Slovenian Research Agency Department of Research Projects - Vanja Rodič, (Authorised Representative, and medical sciences) Scientific Council - Akad. prof. dr. Franc Strle (medical sciences)</p> <p>Slovenian Science Foundation (SZF) - dr. Edvard Kobal, direktor -</p>




<p>Spain</p>	<p>Instituto de salud Carlos III Director - Antonio L. Andreu Pérez Subdirección General de Servicios Aplicados, Formación e Investigación. - Ascensión Bernal Zamora (subdirectora) Escuela Nacional de Sanidad - Luis Guerra Romero (director)</p> <p>Institut d'Estudis de la Salut (IES) - Generalitat Cattelunya Direcció - Sr. Carles Constante i Beitia SUBDIRECCIÓ- Sra. Olinda Ania i Lafuente</p> <p>Ministerio de economía y competitividad Secretaría de Estado de Investigación, Desarrollo e Innovación</p> <p><u>PRIVATE AGENCIES</u></p> <p>Fundació la marató de TV3 Carme Basté Pascual (direcció) Scientific Advisory Board Dra. Marta Aymerich - Depart. Health</p> <p>Fundació La Caixa Enric Banda Tarradellas (Director del Área de Ciencia, Investigación y Medio Ambiente) - secretària: Sra. Cardona</p> <p>FUNDACION ESTHER KOPLowitz fundacionestherkoplowitz@sistelcom.com</p>
<p>Sweden</p>	<p>FAS - Forskningsrådet för Arbetsliv och Socialvetenskap/Swedish Council for Working Life and Social Research Programme Director: Lars Wärngård Public health - Kerstin Carsjö - Work and health - Carin Håkansta / Cecilia Odelstierna</p> <p>VR - Vetenskapsrådet/Swedish Research Council Mille Millnert (Director General) Lena Carlsson (Dept of Molecular and Clinical Medicine)</p> <p>medicine and health: Mats Ulfendahl (Secretary general) - Teresa Ottinger (Coordinator) -</p> <p>Swedish Foundation for Strategic Research, SSF - financing to research in MH or WB is very small part</p> <p>Swedish Foundation for International Cooperation in Research and Higher Education (STINT) - info@stint.se R Medicine - Chair, Professor Ingemar Ernberg</p>

<p>Switzerland</p>	<p>SNF -Schweizerischer Nationalfonds/Fonds National Suisse/Swiss National Science Foundation Research council Division Biology and Medicine - Yilmaz Aysim (Head) http://www.snf.ch/E/about-us/contact/pages/employee-search.aspx?Abteilungslid=697411a5-7a43-48ac-b749-c98c110f4330</p> <p>SPUM (Special programme university medicine) Promotion of young scientists in clinical research by funding multicentric, multidisciplinary clinical projects with a translational character. Division III - Biology and Medicine - E-mail: div3@snf.ch</p>
<p>United Kingdom</p>	<p>MRC - Medical Research Council Rob Buckle - Head, MRC Neuroscience Board Representative: MRC Programme Manager for Mental Health and Addiction - Dr Gavin Malloch</p> <p>Chairman - Donald Brydon - Professor Dame Sally Davies (R&D responsible) - Professor Dame, Sally Macintyre - Director of the Institute of Health and Wellbeing Global Health Group (GHG) - Professor Alan Stein, Head of Section Professor of Child and Adolescent Psychiatry - Neurosciences and Mental Health Board - Professor Hugh Perry, (Chair)</p> <p>Wellcome Trust John Williams - Head of Neuroscience and Mental Health and Head of Clinical Activities nmh@wellcome.ac.uk</p> <p>NIHR – National Institute of Health Research Professor Dame Sally C Davies, Chief Medical Officer and Chief Scientific adviser, Department of Health enquiries@nhr.ac.uk</p> <p>Mental health Foundation Dr Andrew McCulloch, Chief Executive http://www.mentalhealth.org.uk/contact-us/</p> <p>Centre for Mental Health Sean Duggan – Chief Executive contact@centreformentalhealth.org.uk</p>

Annex II. Results display of the database on European training programs to support MH&WB research

First display:



The screenshot shows a web browser window with the URL 'roamer.usn.hu/search.php'. The search filters are set to 'countries: Spain' and 'scientificareas: neuroscience'. The search results show 7 matches. The table below is a transcription of the data displayed in the screenshot.

#	Name	Description	Type	County	City
1	MSc Neuroscience	The main objective of the Master Program is to train future researchers in the field of neuroscience it is intended that students acquire knowledge and practical experience necessary and sufficient to develop their career in the field of neuroscience research. The updated theoretical concepts, practical demonstrations by specialists in each of the subjects and practical training developed by students participating in the program are the best means of giving students the necessary experience to enable them to discern, choose and apply the correct techniques to solve specific problems. It is intended to show students the different lines of work in neuroscience in which they could develop their future activities. Students will be able to integrate all their knowledge and develop different techniques and working methods for solving problems in the field of study of the nervous system. They should be able to make judgments based on information received and to write, present and discuss the basics of each subject. The ultimate goal is to contribute to the training of doctors and scientists to meet the challenges of the 21st century in the study of normal and pathological brain. Students who take the Master may then enter the Ph.D. Graduate Program in Neuroscience.	Masters - taught	Spain	Salamanca
2	MSc Neuroscience	The postgraduate masters in Neuroscience provide solid training in theoretical and practical knowledge of the nervous system cell, molecular, structural, physiological, pharmacology, clinical and behaviour bases. The course integrates knowledge from a wide multidisciplinary perspective providing Medical, Biology, Psychology and general Health professionals with the necessary skills for studying disorders of the nervous system and for learning techniques relating to its study. The aims of the Masters course in Neuroscience are to: - Uncover the foundations to the different fields in neuroscience eg. anatomy, physiology, pharmacology, cellular and molecular biology and psychology. - Provide an understanding of the diverse experimental techniques for exploring the nervous system. - Provide an integrated theoretical and practical base aimed at professionals interested in an in-depth study of the neuroscience field, from physiopathological to clinical mechanisms. - Provide an articulated systematic and gradual knowledge update for diagnosis and treatment of the biological basis for diseases of the nervous system.	Masters - taught	Spain	Palma
3	MSc Neuroscience	The MSc Neuroscience Interuniversity Program taught by the three Galician Universities of Vigo, Santiago de Compostela and Coruna has undergone a major update that will begin to be effective in the 2011-2012 academic year. The change aims to make the course fit the European standard and make it more attractive to new graduates. The most important structural change is that the Master of Neuroscience going to be 60 ECTS instead of 120 ECTS and it will be taught in one academic year instead of two. The number of specialities has been reduced to two in order to increase their quality. There is the possibility of studying part-time over in two academic years.	Masters - taught	Spain	Vigo
4	MSc Neuroscience and Behavioural Biology	The study of the activity, properties and functions of the nervous system will undoubtedly be one of the great challenges of this century. The purpose of the course is to put students in contact with the knowledge that currently exist on the structure and function of the nervous system from a comparative and multidisciplinary perspective. Human and animal aspects of behavioural interaction and individual / media, relations and the plasticity and adaptability of the brain to changes in physical and social environment are studied. Understanding the nervous system also has a manufacturing or industrial interest. One example is the design of new systems, clinical applications or design of drugs that are psycho-neuro-active.	Masters - taught	Spain	Seville
5	MSc Neuroscience and Behavioural Biology	The study of the activity, properties and functions of the nervous system will undoubtedly be one of the great challenges of this century. The purpose of the course is to put students in contact with the knowledge that currently exist on the structure and function of the nervous system from a comparative and multidisciplinary perspective. Human and animal aspects of behavioural interaction and individual / media, relations and the plasticity and adaptability of the brain to changes in physical and social environment are studied. Understanding the nervous system also has a manufacturing or industrial interest. One example is the design of new systems, clinical applications or design of drugs that are psycho-neuro-active.	Masters - taught	Spain	Seville
6	MSc Neurosciences	The objective of this master's degree is to provide you with the training needed to analyse the causes and consequences of disorders of the nervous system and design experimental strategies to discover more about therapeutic treatments for these disorders. You will acquire the following skills: - Understand the components of the nervous system, the cell biology of different neuronal types and glial cells and technical approaches to studying them. - Understand how motor, sensorial and autonomous systems work as well as how integral brain functions act and the techniques used to study them. - Explaining how intermediary metabolism works on the nervous system, chemical neurotransmission processes and pharmacology based receptors, transporters and enzymes of the neurotransmitter metabolism. - Be able to Identify and use research techniques when studying the neurobiological substrates of behaviour, neurodegenerative processes, neuroprotective strategies and techniques used in the repair and plasticity of the nervous system. - Understand the bases of therapeutic treatments applied to nervous system disorders. Career options include research in basic and applied neuroscience: academic Research & Development laboratories or research in the biotechnological or clinical sector dedicated to studying the nervous system and its disorder.	Masters - taught	Spain	Barcelona
7	MSc Physiology and Neuroscience	The Master in Physiology and Neuroscience aim is to train students in knowledge ranging from molecular biology of cell membranes to specific aspects of pathophysiology especially in the structures of the nervous and system from molecular and cellular aspects to behavioural neuroscience. The course objectives are: - To present to students a deeper insight of scientific topics covering the different training modules, Basics and Fundamentals specific methodological Physiology and Neuroscience., - To improve the students training and preparation for their professional, academic or scientific career - Develop in students the ability to use current techniques in the fields of physiology and neuroscience research. - Develop in students the critical skills based on scientific knowledge of the methodology. - Develop the ability to communicate with experts in other fields. - Develop the ability interrelate theory and practical research work -	Masters - taught	Spain	Seville

**** Please note that the tool is still being tested and that could suffer minor changes**

Display of one specific record:



The screenshot shows a web browser window with the URL `roamer.usn.hu/search_res.php?id=101845`. The page content is as follows:

NAME : MSc Neuroscience

DETAILED COURSE DESCRIPTION : The main objective of the Master Program is to train future researchers in the field of neuroscience it is intended that students acquire knowledge and practical experience necessary and sufficient to develop their career in the field of neuroscience research. The updated theoretical concepts, practical demonstrations by specialists in each of the subjects and practical training developed by students participating in the program are the best means of giving students the necessary experience to enable them to discern, choose and apply the correct techniques to solve specific problems. It is intended to show students the different lines of work in neuroscience in which they could develop their future activities. Students will be able to integrate all their knowledge and develop different techniques and working methods for solving problems in the field of study of the nervous system. They should be able to make judgments based on information received and to write, present and discuss the basics of each subject. The ultimate goal is to contribute to the training of doctors and scientists to meet the challenges of the 21st century in the study of normal and pathological brain. Students who take the Master may then enter the Ph.D. Graduate Program in Neuroscience.

TYPE : Masters - taught

COUNTRIES : Spain

CITY : Salamanca

START MONTHS : October

FULL TIME DURATION : 1

FULL TIME DURATION UNITS : Years

PART TIME DURATION :

PART TIME DURATION UNITS :

EU FEES EUROS : 3 000,00 ?

LEARNING CONTEXT : Face-to-Face

TYPE OF CREDITS : ECTS 60

LANGUAGE : Spanish

SCIENTIFIC AREAS : Neuroscience

THERAPEUTIC AREAS : Neurologic disorders

METHODOLOGIES :

AUXILIARY SKILLS :

COURSE CONTACT TITLE :

COURSE CONTACT FIRST NAME : Manuel

COURSE CONTACT LAST NAME : Sanchez Malmierca

COURSE CONTACT DEPARTMENT NAME : The Institute of Neurosciences of Castilla y Leon

COURSE CONTACT JOB TITLE :

COURSE CONTACT TELEPHONE : ?+ 34923294400 ext.75300

COURSE CONTACT EMAIL : incyl@usal.es

ADMIN CONTACT TITLE :

ADMIN CONTACT FIRST NAME : Manuel

COURSE CONTACT LAST NAME : Sanchez Malmierca

COURSE CONTACT DEPARTMENT NAME : The Institute of Neurosciences of Castilla y Leon

COURSE CONTACT JOB TITLE :

COURSE CONTACT TELEPHONE : ?+ 34923294400 ext.75300

COURSE CONTACT EMAIL : incyl@usal.es

ADMIN CONTACT TITLE :

ADMIN CONTACT FIRST NAME : Manuel

ADMIN CONTACT LAST NAME : Sanchez Malmierca

ADMIN CONTACT DEPARTMENT NAME : The Institute of Neurosciences of Castilla y Leon

ADMIN CONTACT JOB TITLE :

ADMIN CONTACT TELEPHONE : ?+ 34923294400 ext.75300

ADMIN CONTACT EMAIL : incyl@usal.es

COURSE PROVIDER NAME : University of Salamanca

COURSE PROVIDER ALPHASORT : Salamanca

COURSE PROVIDER ALSOKNOWNAS : Universidad de Salamanca

** Please note that the tool is still being tested and that could suffer minor changes

Annex III. Database for MH&WB research groups in Europe

***Please note this information is provisional, incomplete and still under revision. It has been extracted from the original Excel file and it is shown just as an example.*

INVESTIGATOR (Author)	COUNTRY	PARTICIPATION IN ROAMER
AARÖ LE	Norway	WP7-Expert
AARSLAND D	France	
ABRAMS D	Sweden	
Adams C	United Kingdom	Clinical research task force
AGERBO E	Denmark	
Agius R	United Kingdom	Clinical research task force
AGUGLIA E	Italy	
AHOLA K	Finland	
ALEMAN A	Netherlands	
ALEXANDERSON K	Sweden	
ALMQVIST F	Finland	
ALONSO J	Spain	WP7-Expert
ALTAMURA C	Italy	Clinical research task force
AMADDEO F	Italy	WP3-Expert; WP6-Expert
AMMINGER GP	austria	
AMORE M	Italy	
ANCKARSÄTER H	Sweden	
ANDERSSON G	Sweden	Clinical research task force
ANDREASSEN O	Norway	
ANDREASSEN OA	Norway	
ANDRES	France	
Anema HJR	Netherlands	Clinical research task force
ANGERMEYER MC	Austria	
AOUIZERATE	France	
ARAKELIAN A	armenia	
ARANGO C	Spain	WP2 - Expert
Araya R	United Kingdom	Clinical research task force
ARNTZ A	Netherlands	WP5-Expert; Clinical research task force
ARO T	Finland	
ARTIGAS F	Spain	
ASGEIRSDOTTIR BB	Iceland	
ASHERSON P	england	
ASKERSTAM M	Sweden	
ASKHEIM OP	Norway	
AUBIN	France	
AURIACOMBE	France	
AYUSO-MATEOS JL	Spain	WP8 - Leader
BÄÄRNHIELM S	Sweden	
BACHOUD-LEVI AC	France	
BAKER MG	United Kingdom	Scientific Advisory Board
BAKKER R	Netherlands	
BALDWIN D	United Kingdom	WP2-Expert
BALESTRIERIX M	Italy	
BALLERINI A	Italy	
BANASCHEWSKI T	germany	Clinical research task force
BARALE F	Italy	
Barbui C	Italy	Clinical research task force
BARON-COHEN S	United Kingdom	WP4-Expert; Clinical research task force
Barrowclough C	United Kingdom	Clinical research task force
BARRY M	Ireland	WP7-Expert
BARTHELEMY	France	
BARTHELEMY C	France	
BASIC J	Croatia	WP3-Expert
BASSI M	Italy	
BATTAGLIA M	Italy	
Bauer	germany	Clinical research task force
BAYLE	France	
BECH P	Denmark	WP8-Expert
Bechdorf A	germany	Clinical research task force

- Interim report -

Becker T	germany	Clinical research task force
BEEKMAN A	Netherlands	WP7-Expert; Clinical research task force
BEKKERING H	Netherlands	
BELIN D	France	
BELLANTUONO C	Italy	
BELLODI L	Italy	
BENEDETTI F	Italy	
BERARDI D	Italy	
Berk M	Australia	Clinical research task force
Berrios GE	United Kingdom	Clinical research task force
Berry K		Clinical research task force
BERTELLI M	Italy	
BERTOLINO A	Italy	
BETANCUR C	France	
BHUGRA D	United Kingdom	WP7-Expert
BICKENBACH J	Switzerland	WP8-Expert
BINDER E	Germany	WP4-Expert
Biondi M	Italy	Clinical research task force
BIONDI M	Italy	
BIONG S	Norway	
BIRCHWOOD M	United Kingdom	WP2-Expert; WP7-Expert
Bird V	United Kingdom	Clinical research task force
BIRKELAND IE	Norway	
BIRMAN S	France	
BIRMES P	France	
BITTER I	Hungary	
BJELLAND AK	Norway	
BJELLAND I	Norway	
BJERTNESS E	Norway	
BJORNER JB	Denmark	
BOBES J	Spain	WP8-Expert
Bogels SM	Netherlands	Clinical research task force
BOGETTO F	Italy	
Bohlmeijer E	Netherlands	Clinical research task force
BOKS M	Netherlands	
BORSBOOM D	Netherlands	
Botbol M	France	Clinical research task force
BOURGERON T	France	
Bowers L	United Kingdom	Clinical research task force
Bowers P	United Kingdom	Clinical research task force
BOYAJYAN A	armenia	
BOYAJYAN AS	armenia	
BOYER P	France	WP3-Expert
BRAMBILLA F	Italy	
BRAMNESS J	Norway	
BROICH K	Germany	WP4-Expert
BROWN VJ	United Kingdom	
BRUFFAERTS R	belgium	
BRUGGEMAN R	Netherlands	
Bruggemann R	Netherlands	Clinical research task force
Brunello N	Italy	Clinical research task force
BRUNT D	Sweden	
Bschor T	germany	Clinical research task force
BUCCI P	Italy	
BUITELAAR J	Netherlands	WP2-Expert; WP4-Expert; Clinical research task force
BUITELAAR JK	Netherlands	Clinical research task force
BURTI L	Italy	
CAFFO E	Italy	
CAHN W	Netherlands	Clinical research task force
Calabrese JR		Clinical research task force
Calati R	Italy	Clinical research task force
CALDAS DE ALMEIDA JM	Portugal	WP7-Expert
Campbell P		Clinical research task force
CAMPION D	France	
CARDOSO G	Portugal	WP7-Expert; Clinical research task force
CARLBRING P	Sweden	
CARLI V	Sweden	WP7-Expert
CARPINIELLO B	Italy	

- Interim report -

CARTA M	Italy	
CASACCHIA M	Italy	
Casas M	Spain	Clinical research task force
CASAS F	Spain	WP8-Expert
CASTEL P	France	
CASTRÉN E	Finland	WP4-Expert
CASTROGIOVANNI P	Italy	
CATAPANO F	Italy	
CATTAN M	United Kingdom	WP7-Expert
CAVALLARO R	Italy	
CECHNICKI A	Poland	WP6-Expert
CHATTERJI S	international	Expert WP8; Clinical research task force
CHERECHEs RM	Romania	WP3-Expert
Chida Y	United Kingdom	Clinical research task force
CHISHOLM D	Switzerland	WP6-Expert; WP8-Expert; Clinical research task force
Churchill	United Kingdom	Clinical research task force
CICCOCIOPPO R	Italy	
CIEZA A	Germany	Expert WP8; Clinical research task force
CLAES L	Belgium	
CLAES S	Belgium	WP2-Expert
Clark D	United Kingdom	Clinical research task force
CLERICI M	Italy	
Cluver L	United Kingdom	Clinical research task force
COCCHI A	Italy	
Coghill D	United Kingdom	Clinical research task force
Cohen A	United Kingdom	Clinical research task force
Cohen D	Netherlands	Clinical research task force
COLOM F	Spain	WP4-Expert; Clinical research task force
COMPAN V	France	
CONTRERAS F	Spain	
COOLS R	Netherlands	WP4-Expert
Cooper B		Clinical research task force
COOPER C	United Kingdom	WP8-Expert
Correll CU		Clinical research task force
Craske MG		Clinical research task force
CUIJERS P	Netherlands	WP6-Expert; WP7-Expert; Clinical research task force
DAHL AA	Norway	
Dainius P	It	WP7-Expert; Clinical research task force
DALE KY	Norway	
DALGARD OS	Norway	
DALGLEISH T	United Kingdom	WP5-Expert
DANIELSSON E	Sweden	
DANION JM	France	
DARDENNES	France	
DAVID D	Romania	WP5-Expert; Clinical research task force
Davidson M		Clinical research task force
Davis JM		Clinical research task force
DAY C	United Kingdom	WP7-Expert
DE ANGELIS MH	Germany	WP3-Expert
DE BARTOLOMEIS A	Italy	
DE BOER H	Netherlands	
DE GIROLAMO G	Italy	WP7-Expert
DE HAAN L	Netherlands	Clinical research task force
DE HERT M	Belgium	Clinical research task force
de Kervasdoue J	France	Scientific Advisory Board; Clinical research task force
DE KLOET ER	Netherlands	WP4-Expert
DE MAN F	Netherlands	WP3-Expert
de Menil V		Clinical research task force
DE RAEDT R	belgium	
DE RONCHI D	Italy	Clinical research task force
DE ROSA C	Italy	
de Ruiter C	Netherlands	Clinical research task force
de Silva M	United Kingdom	Clinical research task force
Deakin B	United Kingdom	Clinical research task force
Dekker J	Netherlands	Clinical research task force
Delespaul P	Netherlands	Clinical research task force
DELL'OSSO B	Italy	Clinical research task force
DELL'OSSO L	Italy	

- Interim report -

DEMARINIS V	Sweden	
Demenil V		Clinical research task force
DEMOTES-MAINARD J	France	WP3 - Co-leader; Clinical research task force
DEMYTTENAERE K	Belgium	
Denys D	Netherlands	Clinical research task force
DENYS D	Netherlands	
D'HARCOURT D	France	
DI GIANNANTONIO M	Italy	
DIDERICHSEN F	Denmark	
DOWRICK C	United Kingdom	WP8-Expert
DUDBAL S	France	
Dumas JM	France	Clinical research task force
EBERHARD-GRAN M	Norway	WP7-Expert
Ebmeier K	United Kingdom	Clinical research task force
EHLERS A	United Kingdom	WP5-Expert; Clinical research task force
EHRENBERG	France	
EHRENBERG A	France	
Ekblad S	Sweden	Clinical research task force
EKEBERG O	Norway	
EKELAND TJ	Norway	
EKELUND J	Finland	
EKLUND M	Sweden	WP8-Expert
EKSELIUS L	Sweden	
EL MESTIKAWY	France	
ELEY TC	United Kingdom	WP5-Expert
ELKLIT A	Denmark	
Elliott R	United Kingdom	Clinical research task force
EIMESTIKAWY S	France	
ELO AL	Finland	
ELOVAINIO M	Finland	
Emmelkamp PMG	Netherlands	Clinical research task force
ENGEDAL K	Norway	
EPELBAUM J	France	
EROLA H	Finland	
ESCERA C	Spain	WP4-Expert
ESKELINEN M	Finland	
EVERS S	Netherlands	WP6-Expert
FAGIOLINI A	Italy	
FALISSARD B	France	
FALKUM E	Norway	
FARAVELLI C	Italy	Clinical research task force
FASSINO S	Italy	
FAVA GA	Italy	WP5-Expert; Clinical research task force
FAVARO A	Italy	
Fegert J	germany	Clinical research task force
FERRANNINI L	Italy	
Ferri C	United Kingdom	Clinical research task force
FERRO F	Italy	
FINSET A	Norway	
FIORILLO A	Italy	Stakeholder Advisory Board
FISCHER G	Austria	
FLEISCHHACKER W	Austria	WP4-Expert
FLEISCHHACKER WW	Austria	WP4-Expert
FLOR H	Germany	WP5-Expert
FORSBERG H	Finland	
FORSELL Y	Sweden	
FOSSATI	France	
FOSSATI P	France	
Fountoulakis KN	Greece	Clinical research task force
FRANCK N	France	
Frangou S	United Kingdom	Clinical research task force
FRANK R	Germany	WP3-Expert
Frasch K	germany	Clinical research task force
FREDEN L	Sweden	
FRIDLUND B	Sweden	
FRIEDLI L	United Kingdom	WP7-Expert
FRIESTAD C	Norway	
FRIIS S	Norway	

- Interim report -

FRITH CD	United Kingdom	WP4-Expert
FROSTHOLM L	Denmark	
Fusar-Poli P	Italy	Clinical research task force
GABRIELLI F	Italy	
GALDERISI S	Italy	
GALLAGHER L	Ireland	WP2-Expert; Clinical research task force
GARCIA R	France	
GARDIER A	France	
Gask L	United Kingdom	Clinical research task force
Geddes J	United Kingdom	Clinical research task force
GERRA G	austria	
Gianella C	Norway	Clinical research task force
GILL M	Ireland	
GILLBERG C	Sweden	Clinical research task force
GIRARDI P	Italy	
GIRAULT H	France	
GIRAULT H	France	
GIROS B	France	
GISSLER M	Sweden	WP3-Expert
Gonda X		Clinical research task force
GOODMAN R	United Kingdom	WP8-Expert; Clinical research task force
Goodwin G	United Kingdom	Scientific Advisory Board; Clinical research task force
GOOSSENS L	Belgium	
GORWOOD P	France	
GOUDEMANT	France	
GRASSI L	Italy	
Grunze H	United Kingdom	Clinical research task force
GUDJONSSON GH	Iceland	
GULACSI L	Hungary	WP6-Expert
GUNNLAUGSSON G	Iceland	
GUSTAFSON Y	Sweden	
HAFFEN	France	
HAGEN KA	Norway	
HÄGGLÖF B	Sweden	
HAGQUIST C	Sweden	
HAHN A	auntria	
HAMMARSTRÖM A	Sweden	
HAMON M	France	WP4-Expert
HANESTAD BR	Norway	
HANSEN V	Norway	
HANSSON L	Sweden	WP3-Expert; WP7-Expert
HARDY	France	
HARDY-BAYLE	France	
HÄRKÄPÄÄ K	Finland	
HARO JM	Spain	Coordinator
Harpham T	United Kingdom	Clinical research task force
Harrison P	United Kingdom	Clinical research task force
Harro J	Estonia	Clinical research task force
HATLING T	Norway	
Hauff E	Norway	Clinical research task force
HAUFF E	Norway	
HAVIK O	Norway	
HEGERL U	Germany	WP7-Expert
HEIERVANG E	Norway	
HEINZ A	Germany	WP4-Expert; Clinical research task force
HELEN H	Finland	
HENIGSBERG N	Croatia	WP4-Expert; Clinical research task force
HENRY	France	
Herpertz-Dahlmann B	germany	Clinical research task force
Hicks MHR		Clinical research task force
HIETALA J	Finland	
HINTERHUBER H	austria	
HOFER A	austria	
HOGL B	austria	
HÖGLEN P	Norway	
HOKKANEN L	Finland	
HOLGERSEN H	Norway	
HOLMES E	United Kingdom	WP5-Expert

- Interim report -

HOLSTEIN B	Denmark	
HOLTE A	Norway	WP5-Expert; WP7-Expert
HONKALAMPI K	Finland	
HONKONEN T	Finland	
HOOGENDIJK W	Netherlands	Clinical research task force
HOPFENBECK M	Norway	
HÖSCHL C	Czech republic	WP3-Expert; WP4-Expert
HOSMAN C	Netherlands	WP7-Expert
HOTOPF M	United Kingdom	
HUIBERS M	Netherlands	
HULSHOF-POL	Netherlands	
HUMMELVOLD JK	Norway	
HUPPERT F	United Kingdom	WP8-Expert
HUSUM TL	Norway	
ISOHANNI M	Finland	
ISOMETSÄ E	Finland	
JACOBSSON L	Sweden	
Jaeger M	Switzerland	Clinical research task force
JANSSEN A	Netherlands	
JARACZ K	Poland	WP8-Expert
JENKINS R	United Kingdom	Scientific Advisory Board; Clinical research task force
JOËLS M	Netherlands	WP2-Expert
JOHANNESSEN J	Norway	
JOHANSSON T	Sweden	
JONES P	United Kingdom	WP2-Expert; WP7-Expert; Clinical research task force
JÖNSSON L	Sweden	WP3-Expert
JÖRGENSEN PM	Denmark	
JOUKAMAA M	Finland	
Joyce E	United Kingdom	Clinical research task force
Juiz JM	Spain	Clinical research task force
JULKUNEN J	Finland	
Kahn R	Netherlands	Clinical research task force
KALEDIENE R	Lithuania	WP7-Expert
KALTIALA-HEINO R	Finland	
KAMPER-JÖRGENSEN F	Denmark	
KAMPMAN O	Finland	
KAPRIO J	Finland	WP4-Expert
Kapur S	United Kingdom	Clinical research task force
KAPUSTA ND	austria	
KARLSEN TI	Norway	
KARLSSON H	Finland	
KARTERUD S	Norway	
KARWAUTZ A	austria	
KASPER S	Austria	Clinical research task force
Kastrup M	dk	Clinical research task force
KATSCHNIG H	Austria	WP7-Expert
KELTIKANGAS-JÄRVINEN L	Finland	
KEMMLER G	austria	
KENNELLY B	Ireland	WP6-Expert
Kerkhof AJFM	Netherlands	Clinical research task force
KESSING L	Denmark	
KESSING LV	Denmark	
KEYSERS C	Netherlands	
KIEFFER B	France	WP4-Expert
KIEFFER BL	France	
Kiejna A	Poland	Clinical research task force
KILIAN R	Germany	WP6-Expert
KIRSCHBAUM C	Germany	WP4-Expert
KIURU L	Finland	
KLAZINGA N	Netherlands	WP7-Expert
Klein J	Hungary	Clinical research task force
KLINGBERG T	Sweden	WP4-Expert
Klosterkoetter J	germany	Clinical research task force
Knapp M	United Kingdom	Scientific Advisory Board; Clinical research task force
Knudsen GM	dk	Clinical research task force
KOCH U	Germany	WP5-Expert; Clinical research task force
Koenig HH	germany	Clinical research task force
KOIVUMAA-HONKANEN H	Finland	WP8-Expert

- Interim report -

KONIG HH	Germany	WP6-Expert
KORHONEN T	Finland	
Kornhuber J	germany	Clinical research task force
Koschorke M	United Kingdom	Clinical research task force
KOSKINEN S	Finland	
KRABBENDAM L	Netherlands	
KREBS M	France	
KREBS MO	France	
KRISTJANSSON AL	Iceland	
KRISTOFFERSEN K	Norway	
KROKSTAD S	Norway	
KRYSPIN-EXNER I	Austria	WP5-Expert; Clinical research task force
Kuhn J	germany	Clinical research task force
KUPKA R	Netherlands	Clinical research task force
LA BARBERA D	Italy	
LAHELMA E	Finland	
LAI T	Estonia	WP3-Expert; WP6-Expert
LAMBREGTS N	Netherlands	
LANCON	France	
LANFUMEY	France	
LANFUMEY L	France	
LANG	France	
LANZENBERGER R	Austria	
LASALVIA A	Italy	WP6-Expert
LAWLOR B	Ireland	WP2-Expert
LAWLOR BA	Ireland	
LEBOUCHER	France	
LEBOUCHER P	France	
LEBOYER M	France	WP3 - Leader; Clinical research task force
LECIC-TOSEVSKI D	Serbia	WP3-Expert
LEENTJENS A	Netherlands	Clinical research task force
Leff J	United Kingdom	Clinical research task force
Lehmkuhl G	germany	Clinical research task force
LEINONEN E	Finland	
Leonard B	Ireland	Clinical research task force
LEPINE JP	France	
LESCH KP	Germany	WP4-Expert; Clinical research task force
Levav I	il	Clinical research task force
Levi L	Sweden	Clinical research task force
LEWIS S	United Kingdom	WP11 - Co-Leader; Clinical research task force
LIEN L	Norway	
LINAKE O	Norway	
LINDBERG N	Finland	
LINSZEN D	Netherlands	Scientific Advisory Board
LINSZEN DH	Netherlands	
Livingston G	United Kingdom	Clinical research task force
LJUNGBERG T	Sweden	
Lovestone S	United Kingdom	Clinical research task force
Lowe B	germany	Clinical research task force
LUND A	Norway	
LUNDERVOLD A	Norway	
LUNDERVOLD AJ	Norway	
LUNDH LG	Sweden	
LUNDBERG I	Sweden	
LUTZ W	Germany	WP5-Expert; Clinical research task force
MAFFEI C	Italy	
MAGGINI C	Italy	
MAIER W	Germany	WP4-Expert; Clinical research task force
MAINA G	Italy	
MAJ M	Italy	Stakeholder Advisory Board; Clinical research task force
MALLET Y	France	
MAMELI M	France	
MANCHIN R	Belgium	
Maniglio R	Italy	Clinical research task force
MANN K	Germany	WP4-Expert
MANZONI O	France	
MARAZZITI D	Italy	
MARIN O	Spain	Scientific Advisory Board

- Interim report -

MARSICANO G	France	
Martinet JL	France	Clinical research task force
MARTINOT JL	France	
MARTINSEN EW	Norway	
MARTORELL A	Spain	
MARTTUNEN M	Finland	
Marwijk H	Netherlands	Clinical research task force
Mataix-Cols D	United Kingdom	Clinical research task force
MATSCHINGER H	germany	
MAURI M	Italy	
McConachie H	United Kingdom	Clinical research task force
MCCRONE P	United Kingdom	WP6-Expert
MCDALD D	United Kingdom	WP6 - Leader; Clinical research task force
MCGUIRE P	United Kingdom	WP2-Expert
MEEUWISSE A	Sweden	
MEHLUM L	Norway	
MELLE I	Norway	
MENCACCI C	Italy	
MENDLEWICZ J	belgium	
MEYER-LINDENBERG A	Germany	WP2-Expert; WP4-Expert
MIETTUNEN J	Finland	
MIGLIACCIO G	Italy	
MILES R	France	
Miranda J	United Kingdom	Clinical research task force
Mitchell AJ	United Kingdom	Clinical research task force
MITTERHAUSER M	austria	
MO TO	Norway	
Moeller HJ	germany	Clinical research task force
MONTELEONE P	Italy	
MORITZ S	Germany	WP2-Expert
MORKEN G	Norway	
MORTENSEN EL	Denmark	
MORTENSEN PB	Denmark	WP3-Expert
MRAZEK F	Czech rep.	
MUCCI A	Italy	
MUIJEN M	Denmark	WP7-Expert
Mulder NCL	Netherlands	Clinical research task force
MUNK-OLSEN T	Denmark	
Murray J	United Kingdom	Clinical research task force
Murray R	United Kingdom	Scientific Advisory Board
MUSCETTOLA G	Italy	
MYKLETUN A	Norway	WP7-Expert
NAASSILA M	France	
NABER D	Germany	WP8-Expert
NARDINI M	Italy	
NAUDIN	France	
NIEMELÄ S	Finland	
NOBLE F	France	
NOLEN W	Netherlands	
NORDENTOFT M	Denmark	WP7-Expert
NUTT D	United Kingdom	WP4-Expert; Clinical research task force
NUTT DJ	United Kingdom	
NYBO T	Finland	
O'BRIEN J	United Kingdom	WP2-Expert; Clinical research task force
Odegaard K	Norway	WP4-Expert; Clinical research task force
ÖDEGAARD K	Norway	
Ögren SO	Sweden	Clinical research task force
ÖJEHAGEN A	Sweden	
OLDEWINKEL T	Netherlands	
OLSSON I	Norway	
ORMEL H	Netherlands	
OSWALD A	United Kingdom	WP8-Expert
Owen M	United Kingdom	Scientific Advisory Board; Clinical research task force
ØYE C	Norway	
Oyebode F	United Kingdom	Clinical research task force
PALLANTI S	Italy	
PARIANTE C	United Kingdom	WP2-Expert
PARIANTE CM	United Kingdom	

- Interim report -

PASSERIEUX C	France	
Patel V	United Kingdom	Clinical research task force
PAUNIO T	Finland	
PAZOS A	Spain	WP3-Expert
PEDERSEN R	Norway	
PEDERSEN W	Norway	
PEETERS F	Netherlands	
PELISSOLO A	France	
Peltonen K	Finland	Clinical research task force
PENNINX B	Netherlands	
PERETTI	France	
PERNA G	Italy	
PERUGI G	Italy	
PESSIGLIONE M	France	WP4-Expert
Petermann	germany	Clinical research task force
PETREK M	Czech rep.	
PEUSKENS J	BELGIUM	
Pfennig A	germany	Clinical research task force
PIAZZA PV	France	
PIHA J	Finland	
PILGRIM D	United Kingdom	WP7-Expert
PINI S	Italy	
Pinquart M	germany	Clinical research task force
PIRILÄ S	Finland	
PIRKOLA S	Finland	
PLACIDI GF	Italy	
POEWE W	Austria	
POSADA-VILLA J	Colombia	
Pot AM	Netherlands	Clinical research task force
Pouwer F	Netherlands	Clinical research task force
Preux PM	France	Clinical research task force
PRIEBE S	United Kingdom	WP3-Expert; Clinical research task force
Prince M	United Kingdom	Clinical research task force
Prost A	United Kingdom	Clinical research task force
QUARTESAN R	Italy	
Raboch J	Czech Republic	Clinical research task force
RAHKONEN O	Finland	
Rahman A	United Kingdom	Clinical research task force
RAIHA H	Finland	
RAIKKONEN K	Finland	
RÄIKKÖNEN K	Finland	
RAMSDAL H	Norway	
RAMSEY N	Netherlands	
RÄB M	Germany	
RÄTY H	Finland	
RAVENS-SIEBERER U	Germany	WP8-Expert
REHM J	Germany	WP2-Expert; Clinical research task force
REICHBORN-KJENNERUD T	Norway	
Reif A	germany	Clinical research task force
REYMANN KG	Germany	
REYNAUD	France	
RIEF W	Germany	WP5-Expert; Clinical research task force
RIGATELLI M	Italy	
RIHMER Z	Hungary	WP4-Expert; Clinical research task force
RIPER H	Netherlands	WP3-Expert
RITCHIE K	France	
ROBBINS TW	United Kingdom	WP2-Expert; WP4-Expert; Clinical research task force
Roberts B	United Kingdom	Clinical research task force
ROCCA P	Italy	
ROEYERS H	BELGIUM	
ROISER J	United Kingdom	WP4-Expert
Roncero C	Spain	Clinical research task force
RONCONE R	Italy	
ROSE D	United Kingdom	WP2-Expert
ROSSI A	Italy	
ROSSINI PM	Italy	WP4-Expert
ROTHENBERGER A	Germany	Clinical research task force
ROUILLON	France	

- Interim report -

ROYSAMB E	Norway	WP8-Expert
RØYSAMB E	Norway	WP8-Expert
RUGGERI M	Italy	WP7-Expert
RUGULIES R	Denmark	
RUINI C	Italy	WP8-Expert
RUJESCU D	Germany	
RUSCH N	Switzerland	WP6-Expert
RUSSO J	Germany	WP3-Expert; WP6-Expert
RUTTER M	United Kingdom	WP4-Expert
RUUD T	Norway	WP7-Expert
RYBAKOWSKI J	Poland	WP4-Expert
RYBAKOWSKI JK	Poland	WP4-Expert
RYBECK AK	Sweden	
SACCHETTI E	Italy	
SAHAKIAN B	United Kingdom	WP4-Expert
SAHAKIAN BJ	United Kingdom	
SALIZE HJ	Germany	WP7-Expert
SALOKANGAS R	Finland	WP2-Expert; WP7-Expert; Clinical research task force
SALOKANGAS RKR	Finland	
SALVADOR-CARULLA L	Spain	WP6-Expert; WP8-Expert
SANDI C	Switzerland	WP4-Expert
SANJUÁN J	Spain	
SANTALAHTI P	Finland	
SANTONASTASO P	Italy	
SARCHIAPONE M	Italy	
SAVLI M	austria	
SCARONE S	Italy	
SCHEEPERS F	Netherlands	
SCHENE A	Netherlands	Clinical research task force
SCHERRMANN JM	France	
SCHIENLE A	austria	
SCHIEVELD J	Netherlands	
SCHMIDT L	Denmark	
SCHOENBERG S	Germany	WP3-Expert
Schoevers RA	Netherlands	Clinical research task force
SCHOEVERS R	Netherlands	Clinical research task force
SCHRUERS K	Netherlands	
Schubert A	eu	Clinical research task force
SCHUMANN G	United Kingdom	WP4 - Leader; Clinical research task force
Scott J	United Kingdom	Clinical research task force
SECKL JR	United Kingdom	
SELTEN JP	Netherlands	
SENON	France	
SERRETTI A	Italy	Clinical research task force
SHARPE M	United Kingdom	WP7-Expert; Clinical research task force
SIGFUSDOTTIR ID	Iceland	
SIGURDSSON JF	Iceland	
SINGER T	Germany	
SINGEWALD N	austria	
Singh SP	United Kingdom	Clinical research task force
SIRACUSANO A	Italy	
SIVERTSEN B	Norway	
SJÖSTRÖM S	Sweden	
SKÅRSÅTER I	Sweden	
SKOOG I	Sweden	Clinical research task force
SKOVGAARD AM	Denmark	
Slade M	United Kingdom	Clinical research task force
SMEDLER AC	Sweden	
SMERALDI E	Italy	
SMIT F	Netherlands	WP6-Expert
SMITH A	United Kingdom	
SOBOCKI P	Sweden	WP3-Expert
Soellner W	germany	Clinical research task force
SOMMERS I	Netherlands	
Sonuga-Barke EJB	United Kingdom	Clinical research task force
SØRLIE T	Norway	
SOUERY D	belgium	
SOURANDER A	Finland	

- Interim report -

SPANAGEL R	Denmark	WP4-Expert
SPECKENS A	Netherlands	
Spijker J	Netherlands	Clinical research task force
SPINDELEGGER C	austria	
Spinhoven P	Netherlands	Clinical research task force
STAAL W	Netherlands	
STANGHELLINI G	Italy	
STARACE F	Italy	
STEFAN KE	Switzerland	WP4-Expert
Stein A	United Kingdom	Clinical research task force
STEINHAUSEN HC	switzerland	Clinical research task force
Steptoe A	United Kingdom	Clinical research task force
STEWART-BROWN S	United Kingdom	WP7-Expert; WP8-Expert
SUHR S	United Kingdom	
SUNDET K	Norway	
SUNDVALL M	Sweden	
SUVISAARI J	Finland	
SVAB I	Slovenia	WP3-Expert
SVAB V	Slovenia	WP6-Expert
SYDSJÖ G	Sweden	
TAMBS K	Norway	
TAMMINEN T	Finland	WP2-Expert; WP7-Expert
TANSELLA M	Italy	
TANUM L	Norway	
Tarrier N	United Kingdom	Clinical research task force
TASSIN JP	France	
TAUBE M	Latvia	WP7-Expert
Taylor D	United Kingdom	Clinical research task force
Taylor PJ	United Kingdom	Clinical research task force
Thomas FC	United Kingdom	Clinical research task force
Thome J	germany	Clinical research task force
THORNICROFT G	United Kingdom	WP6 - Co-leader; Clinical research task force
THORNTON J	United Kingdom	WP3-Expert
TIIHONEN J	Finland	
TODARELLO O	Italy	
TOMASELLO M	Germany	WP4-Expert
TOMASSON K	Iceland	WP7-Expert
TOPOR A	Sweden	
TORTORELLA A	Italy	
TRICKLEBANK M	United Kingdom	WP4-Expert
TROISI A	Italy	
TRONCHE F	France	
TUSETH AG	Norway	
Tyrer P	United Kingdom	Clinical research task force
UCOK A	Turkey	WP6-Expert
Underhill C	United Kingdom	Clinical research task force
VALDIMARSDOTTIR HD	Iceland	
VÄLIMÄKI M	Finland	WP7-Expert
VAN AMELSVOORT T	Netherlands	
VAN AUDENHOVE C	Belgium	WP6-Expert; Clinical research task force
van Busschbach	Netherlands	Clinical research task force
van de Put W		Clinical research task force
van de Brink W	Netherlands	Clinical research task force
VAN DER FELTZ-CORNELIS C	Netherlands	WP2 - Co-leader; Leader of the Clinical research task force; WP7-Expert
VAN DER GAAG M	Netherlands	
VAN DER GAAG RJ	Netherlands	
VAN DER WEE N	Netherlands	Clinical research task force
van Dijk F	Netherlands	Clinical research task force
van Ginneken N	United Kingdom	Clinical research task force
VAN HARTEN P	Netherlands	
VAN HEMERT B	Netherlands	Clinical research task force
van Ijzendoorn MH	Netherlands	Clinical research task force
VAN IJZENDOORN R	Netherlands	WP4-Expert
van Ommeren M	international	Clinical research task force
VAN OS J	Netherlands	WP2 - leader; Clinical research task force
VAN PRAAG H	Netherlands	
van Straten A	Netherlands	Clinical research task force
van Voren R		Clinical research task force

- Interim report -

VAN WEEGHEL J	Netherlands	WP6-Expert; Clinical research task force
VAN WINKEL R	belgium/netherlands	
Vancampfort D	belgium	Clinical research task force
VÄRNIK A	Estonia	WP7-Expert
VAUGEOIS JM	France	
VÁZQUEZ C	Spain	
VEENHOVEN R	Netherlands	WP8-Expert
VEIJOLA J	Finland	
VENTEGODT S	Denmark	
Ventevogel P		Clinical research task force
VERBANCK P	Belgium	
VERDOUX H	France	
Verheul R	Netherlands	Clinical research task force
VERHEY F	Netherlands	
VERHULST F	Netherlands	
VERKES R	Netherlands	
VERMEIRE R	Netherlands	
Vermeiren R	Netherlands	Clinical research task force
VIETA E	Spain	WP2-Expert; WP4-Expert; Clinical research task force
VIINAMAKI H	Finland	
VIINAMÄKI H	Finland	
VINGERHOETS AJJM	Netherlands	WP8-Expert
VIRTANEN M	Finland	
VIRTANEN P	Finland	
VITA A	Italy	
VITTERSØ J	Norway	WP8-Expert
Vollebergh W	Netherlands	Clinical research task force
VOLPE U	Italy	
VON KNORRING L	Sweden	
VORACEK M	austria	
VORSTMAN J	Netherlands	
VUORI J	Finland	WP7-Expert
VUORIO E	Finland	
WADDINGTON JL	Ireland	
WADSAK W	austria	
WAHLBECK K	Finland	WP7 - Leader; Clinical research task force
WAHLBERG KE	Finland	
WALBURG J	Netherlands	WP2-Expert; Clinical research task force
WALDEMAR G	Denmark	
WASSERMAN D	Sweden	
WENIGOVA B	Czech republic	WP6-Expert
Wessely S	United Kingdom	Clinical research task force
WESTERHOF G	Netherlands	WP8-Expert
WESTERLUND H	Sweden	
WEYERER S	Germany	WP2-Expert
WICHERS M	Netherlands	
WIESELGREN IM	Sweden	
WINBLAD B	Sweden	
WITTCHEN HU	Germany	WP5 - Leader; Clinical research task force
WYKES T	United Kingdom	WP11 - Leader; Clinical research task force
YELNIK J	France	
Young AH	United Kingdom	Clinical research task force
ZACHARIAE R	Denmark	
ZAKHARYAN R	armenia	
ZATLOUKAL K	Austria	
ZECHMEISTER I	Austria	WP6-Expert
ZITMAN L	Netherlands	
ZLATI A	Romania	WP6-Expert
ZOHAR J	israel	
	France	Clinical research task force